Olanzapine treatment for dopaminergic-induced hallucinations.
about
Quetiapine in the treatment of psychosis in Parkinson's diseasePresentation and management of psychosis in Parkinson's disease and dementia with Lewy bodiesThe Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseaseEvidence for the use of pimavanserin in the treatment of Parkinson's disease psychosisPsychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Treatment of psychosis and dementia in Parkinson's disease.Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's diseasePimavanserin for the treatment of Parkinson's disease psychosis.Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Behavioral effects of levodopa.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Parkinson's psychosis.An update expert opinion on management and research strategies in Parkinson's disease psychosisDopamine agonists in Parkinson's disease.Pharmacologic management of psychosis in the elderly: a critical review.Psychotic symptoms in Parkinson's disease: pathophysiology and management.Physician response to a medication alert system in inpatients with levodopa-treated diseases.Treatment of behavioural symptoms and dementia in Parkinson's disease.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies.The management of psychosis in movement disorder patients.Management of the behavioral aspects of Parkinson's disease.Current approaches to the treatment of Parkinson's diseaseNew approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital.Atypical antipsychotic drugs in the treatment of Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.The psychosis spectrum in Parkinson disease.Neuropsychiatric Issues in Parkinson's Disease.Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders: A Systematic Review.Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.Current Understanding of Psychosis in Parkinson's Disease.Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
P2860
Q24628941-A873D31C-2AA4-4F50-8DE4-91C29E3D7D53Q24680260-E7E52EE0-E1ED-44AF-8F59-F6EC633F14F0Q26738456-107E5561-0A80-41E6-BDFB-3D4AD818265DQ28074468-070D7E1B-4C7B-43E0-B686-0B4C1F460A0CQ30249553-09B023B6-0D8A-47D5-AEAA-86B3A1CA8F38Q30358337-81ED2C58-5F3D-4ABC-B0A7-B5E988453AD9Q30489967-C0C9E2DC-26DD-47C2-B2F6-76480D5FECB9Q33260251-2DD7B8D1-ADBC-4895-A42E-7AFDA74AF31FQ33607256-72AECA0C-C10B-48C3-A226-6A5DCC401563Q34369646-AC16EB1B-1994-49BC-9DB3-4047DAD5D5B0Q34388686-0412C714-4448-45EC-852B-582F819B009DQ34452922-477EF108-B9A2-42FC-84C9-33D1A8116449Q34610593-045477D8-BB92-494B-9805-55F181E1F7BFQ34610608-6E48BC52-0806-4541-A4DB-37E30ECB575FQ34610632-8743CEC2-0FD3-46C0-932B-43812FA873B5Q35154278-6B9FDB31-E758-4660-8546-F9037F0CA0F3Q35570952-0B087A71-1FDD-4A7E-9495-3F6B7B691D69Q35599469-4B3E85B6-9787-4049-BEEE-B575BE7C581FQ35779329-16A43566-6313-4651-AF78-50690A530473Q35945757-ED5B9FDF-9F7E-4B68-BDB6-8B8A96027338Q36089350-B7E958DB-7162-4771-BFEF-5FA71C8C45C2Q36425995-13C22F2B-FEF3-4013-8B15-5EF6EF720B3DQ36806669-8759B955-2DBB-4070-9887-DA84F218289AQ36808034-93CA77F4-460C-42A4-80A5-709F9DE2DBDCQ36847271-B95050BA-8678-4D5F-830F-BAC17A8CD754Q36876438-1F838192-0685-4D82-9532-57941DC9D4F0Q37021326-BE06A6FD-7E41-4B31-A174-D6A8FF874BFEQ37853032-9C4513A6-36EE-4AF9-80A2-DC9C6C4D2036Q37862378-09498B2F-87B4-4D9E-8223-E051F34F233CQ37957772-CCADD4B5-1973-490E-A3F2-B0A4AB038BAAQ38070888-372CAACA-43E6-4F97-96F3-2EB1A45B4DD0Q38258699-B7F81558-06E9-4821-91B5-5EBC5A6E2B45Q38588201-CA5844EF-E10B-4326-8955-B6F8327712ACQ38662579-36120102-781F-4527-A020-38A32315E5E8Q38768169-7891EBBD-359E-4231-81E5-71A5EC403869Q38799051-1E98BDE1-8E17-45A6-AB5A-E4C7D3A09216Q38801245-A899C818-4E50-4EE7-A9FE-3ADE90D17BBEQ38849634-3AA95D28-8DBF-4AEA-B109-722C50914BE0Q38954642-C3D426D2-3923-40BE-9CC3-46CB0FD5AADEQ39004255-D837B87E-710F-4F58-9045-FE29A152A8D3
P2860
Olanzapine treatment for dopaminergic-induced hallucinations.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Olanzapine treatment for dopaminergic-induced hallucinations.
@en
Olanzapine treatment for dopaminergic-induced hallucinations.
@nl
type
label
Olanzapine treatment for dopaminergic-induced hallucinations.
@en
Olanzapine treatment for dopaminergic-induced hallucinations.
@nl
prefLabel
Olanzapine treatment for dopaminergic-induced hallucinations.
@en
Olanzapine treatment for dopaminergic-induced hallucinations.
@nl
P2093
P2860
P356
P1433
P1476
Olanzapine treatment for dopaminergic-induced hallucinations.
@en
P2093
Christine Hunter
Joel K Levy
Kevin Dat Vuong
William G Ondo
P2860
P304
P356
10.1002/MDS.10217
P407
P577
2002-09-01T00:00:00Z